FOLLISTATIN 315
Interesting mechanistic differences from FS-344, but the research base remains quite thin with only one human study among nine total investigations. The tissue-targeting concept is scientifically sound, but we need much more data to understand real-world effects.
Primarily investigated by muscle wasting researchers and scientists studying sarcopenia in aging populations.
Since Feb 2026
9 total, 1 human
What is FOLLISTATIN 315?
Among the different forms of follistatin found naturally in the body, the 315 variant stands out for its ability to stay put where it's produced rather than circulating throughout the bloodstream. Muscle researchers are particularly interested in this isoform because it appears to block myostatin—a protein that limits muscle growth—right at the cellular level where it matters most. This localized action makes it an intriguing subject for studies on muscle wasting conditions and age-related muscle loss.
The key difference lies in FS-315's molecular structure, which includes a heparin-binding domain that acts like a cellular anchor, keeping the protein attached to specific tissues rather than floating freely in circulation. When myostatin tries to signal muscle cells to stop growing or start breaking down protein, FS-315 intercepts these signals by physically binding to myostatin molecules before they can reach their cellular targets. Think of it as a highly specific bouncer that only blocks the signals telling muscles to shrink or weaken.
What the Research Shows
With only 9 studies total and just 1 involving human participants, the research foundation is still in its early stages.
Notable Studies
Fujiwara T, Sidis Y, Welt C et al. · J Clin Endocrinol Metab (2001)
Cohort · n=11
Canali S, Core AB, Zumbrennen-Bullough KB et al. · Endocrinology (2016)
Animal
Datta-Mannan A, Yaden B, Krishnan V et al. · J Pharmacol Exp Ther (2013)
Animal · Phase 1
Ungerleider NA, Bonomi LM, Brown ML et al. · Endocrinology (2013)
Animal
Lin SY, Morrison JR, Phillips DJ et al. · Reproduction (2003)
Review
Reported Benefits
Regulatory Status
Last verified: Feb 2026
Related Peptides
This information is for research purposes only and does not constitute medical advice. Always consult a licensed physician before using any peptides.